Analyzing Precipio (PRPO) and Its Rivals

Precipio (NASDAQ:PRPO) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it contrast to its competitors? We will compare Precipio to similar companies based on the strength of its risk, dividends, earnings, valuation, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares Precipio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Precipio Competitors	-8.08%	-137.95%	-1.47%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Precipio and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1	0	0	0	1.00
Precipio Competitors	1861	7721	13336	820	2.55

As a group, “Healthcare Providers & Services” companies have a potential upside of 13.51%. Given Precipio’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Precipio has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

10.4% of Precipio shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 16.6% of Precipio shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Precipio has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Precipio’s competitors have a beta of 0.98, meaning that their average share price is 2% less volatile than the S&P 500.

Earnings and Valuation

This table compares Precipio and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Precipio	$27.20 million	-$360,000.00	-29.88
Precipio Competitors	$19.16 billion	$301.67 million	7.60

Precipio’s competitors have higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Precipio competitors beat Precipio on 9 of the 13 factors compared.

About Precipio

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.